Advertisement

Surgical Management of Hypertrophic Cardiomyopathy

  • William G. Williams
  • E. Douglas Wigle
  • Harry Rakowski
  • Anthony C. Ralph-Edwards
  • Leonard Schwartz
Chapter
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by ventricular hypertrophy in the absence of an identifiable cause for the hypertrophy (1, 2, 3, 4). The hypertrophy is usually asymmetric and involves the interventricular septum in 90% of patients. Most commonly, the outflow septum (i.e., subaortic area) is the major focus of hypertrophy, but the midventricular or apical septum may occur in isolation or concomitantly. Rarely (5%) the right ventricle is involved. The extent of the hypertrophy varies tremendously and accounts for different manifestations of the disease (1, 2, 3, 4, 5). The hypertrophy is associated with myocardial fiber disarray on microscopy.

Keywords

Mitral Valve Leave Atrial Hypertrophic Cardiomyopathy Left Ventricular Outflow Tract Myocardial Contrast Echocardiography 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995;92:1680–1692.PubMedGoogle Scholar
  2. 2.
    Spirito P, Sideman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775–785.PubMedCrossRefGoogle Scholar
  3. 3.
    Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127–133.PubMedCrossRefGoogle Scholar
  4. 4.
    Maron BJ, Salberg L. Hypertrophic Cardiomyopathy: For Patients, Their Families, and Interested Physicians. Futura, New York: 2001.Google Scholar
  5. 5.
    Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650–655.PubMedCrossRefGoogle Scholar
  6. 6.
    Maron BJ, Moller JH, Seidman CE, et al. Impact of laboratory molecular diagnostic criteria for genetically transmitted cardiovascular diseases: hypertrophic cardiomyopathy. Long QT syndrome, and Marfan syndrome. Circulation 1998;98:1460–1471.Google Scholar
  7. 7.
    Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocar-diographic analysis of 4111 subjects in the CARDIA study. Circulation 1995;92:785–789.PubMedGoogle Scholar
  8. 8.
    Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and extent of the hypertrophy. A review. Prog Cardiovasc Dis 1985;28:l–83.CrossRefGoogle Scholar
  9. 9.
    Hecht GM, Panza JA, Maron BJ. Clinical course of middle-aged asymptomatic patients with hypertrophic cardiomyopathy. Am J Cardiol 1992;69:935–940.PubMedCrossRefGoogle Scholar
  10. 10.
    Yetman A, Hamilton R, Benson L, McCrindle BW. Factors associated with outcome in children with hypertrophic cardiomyopathy. Can J Cardiol 1997;13:88C.Google Scholar
  11. 11.
    Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R. Myocardial bridging in children with hypertrophic cardiomyopathy—a risk factor for sudden death. N Engl J Med 1998;339:1201–1209.PubMedCrossRefGoogle Scholar
  12. 12.
    Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778–1785.PubMedCrossRefGoogle Scholar
  13. 13.
    Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death. Circulation 2000;102:858–864.PubMedGoogle Scholar
  14. 14.
    Doevendans PA. Hypertrophic cardiomyopathy: do we have the algorithm for life and death? Circulation 2000;101:1224–1226.PubMedGoogle Scholar
  15. 15.
    Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons < 40 years of age. Am J Cardiol 1991;68:1388–1392.PubMedCrossRefGoogle Scholar
  16. 16.
    Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994;90:2743–2747.PubMedGoogle Scholar
  17. 17.
    Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patient. J Am Coll Cardiol 2000;36:2212–2218.PubMedCrossRefGoogle Scholar
  18. 18.
    McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy: assessment of patients at high risk. Circulation 1989;80:1489–1492.PubMedGoogle Scholar
  19. 19.
    Elliott PM, Sharma S, Varnava A, Poloniecki J, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:1596–1601.PubMedCrossRefGoogle Scholar
  20. 20.
    Wigle ED, Rakowski H. Hypertrophic cardiomyopathy: when do you diagnose midventricular obstruction vs apical cavity obliteration with a small nonobliterated area at the apex of the left ventricle? J Am Coll Cardiol 1992;19:525–526.PubMedGoogle Scholar
  21. 21.
    Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol 1992;20:53–54.Google Scholar
  22. 22.
    Yu E, Chiam C, Siu S, Rakowski H, Wigle ED, O’Kelly B. Left atrial structure and function post myectomy in patients with hypertrophic obstructive cardiomyopathy. Can J Cardiol 1997;13:95C.Google Scholar
  23. 23.
    Yu EHC, Omran AS, Wigle D, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000;36:2219–2225.PubMedCrossRefGoogle Scholar
  24. 24.
    McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985;53:412–416.PubMedCrossRefGoogle Scholar
  25. 25.
    Gilligan DM, Missouris CG, Boyd MJ, Oakley CM. Sudden death due to ventricular tachycardia during Amiodarone therapy in familial hypertrophic cardiomyopathy. Am J Cardiol 1991;68:971–973.PubMedCrossRefGoogle Scholar
  26. 26.
    Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365–373.PubMedCrossRefGoogle Scholar
  27. 27.
    McDonald K, McWilliams E, O’Keefe B, Maurer B. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. Eur Heart J 1988;9:893–898.PubMedGoogle Scholar
  28. 28.
    Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 1999;99:2927–2933.PubMedGoogle Scholar
  29. 29.
    Williams WG, Wigle ED, Rakowski H, Smallhorn J, Leblanc J, Trusler GA. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation 1987;76:V104–V108.PubMedGoogle Scholar
  30. 30.
    Williams WG, Ralph-Edwards AC, Wigle ED. Surgical management of hypertrophic obstructive cardiomyopathy. Cardiol Rev 1997;5:40–49.CrossRefGoogle Scholar
  31. 31.
    Theodora DA, Danielson GK, Feldt RH, Anderson BJ. Hypertrophic obstructive cardiomyopathy in pediatric patients: results of surgical treatment. J Thorac Cardiovasc Surg 1996;112:1589–1599.CrossRefGoogle Scholar
  32. 32.
    Heric B, Lytle BW, Miller DP, et al. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg 1995;110:195–208.PubMedCrossRefGoogle Scholar
  33. 33.
    McCully RB, Nishimura RA, Tajik AJ, et al. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1999;99:2927–2933.Google Scholar
  34. 34.
    Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance of intraoperative decision making. J Am Coll Cardiol 1992;53:42–52.CrossRefGoogle Scholar
  35. 35.
    Cregg N, Cheng DCH, Karski JM, Williams WG, Webb G, Wigle ED. Morbidity outcome in patients with hypertrophic obstructive cardiomyopathy undergoing cardiac septal myectomy: early-extubation anesthesia vs high-dose opioid anesthesia technique. J Cardiothorac Vase Anesthesia 1999;13:47–52.CrossRefGoogle Scholar
  36. 36.
    Sigwart U. Nonsurgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211–214.PubMedCrossRefGoogle Scholar
  37. 37.
    Faber L, Seggewiss H, Fassbender D, et al. Identification of the target vessel (TV) in percutaneous transluminal ablation (PTSMA) in hypertrophic obstructive cardiomyopathy by myocardial contrast echocardiography (MCE) [abstract]. Circulation 1997;96(suppl I):I–639.Google Scholar
  38. 38.
    Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer WH, Nagueh SF. Echocardiographic insight into the mechanisms of relief of left ventricular obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;37:208–214.PubMedCrossRefGoogle Scholar
  39. 39.
    Woo A, Schwartz L, Wigle ED, Ross J, Rakowski H. Myocardial contrast echocardiography during septal ethanol ablation for obstructive hypertrophic cardiomyopathy. In: Goldberg BB, Raichlen JS, Forsberg F, eds. Ultrasound Contrast Agents. Martin Dunitz: 2000, pp. 197–211.Google Scholar
  40. 40.
    Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 2001; 103:1492–1496.PubMedGoogle Scholar
  41. 41.
    Li G, Li R-K, Mickle DAG, et al. Elevated insulin-like growth factor-1 and transforming growth factor-BI and their receptors in patients with idiopathic hypertrophic obstructive cardiomyopathy. Circulation 1998;98:II-144–II-150.Google Scholar
  42. 42.
    Li G, Li R-K, Borger MA, et al. Regional overexpression of IGF-1 and TGF-B1 in the myocardium of hypertrophic obstructive cardiomyopathy patients. J Thorac Cardiovasc Surg 2002;123:89–95.PubMedCrossRefGoogle Scholar
  43. 43.
    Seggewiss H, Gleichman U, Faber L, et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3 month follow-up in 25 patients. J Am Coll Cardiol 1998;31:252–258.PubMedCrossRefGoogle Scholar
  44. 44.
    Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet 2000;355:425–426.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • William G. Williams
    • 1
  • E. Douglas Wigle
    • 2
  • Harry Rakowski
    • 3
  • Anthony C. Ralph-Edwards
    • 3
  • Leonard Schwartz
    • 3
  1. 1.Division of Cardiovascular Surgery, Department of MedicineThe Hospital for Sick Children, University of TorontoTorontoCanada
  2. 2.Division of Cardiovascular Surgery, Department of MedicineUniversity of TorontoTorontoCanada
  3. 3.Division of Cardiovascular SurgeryUniversity of TorontoTorontoCanada

Personalised recommendations